Practical strategies for suppressing hypoxia-inducible factor activity in cancer therapy

Medical Hypotheses

Volumn 74, Issue 5, 2010, Pages 789-797

  McCarty, Mark F ^a   Barroso Aranda, Jorge ^a   Contreras, Francisco ^a  

^a Oasis of Hope Hospital   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOGLUTARIC ACID; ACETYLCYSTEINE; ANTHRACYCLINE; ASCORBIC ACID; BEVACIZUMAB; CARDIAC GLYCOSIDE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DIGOXIN; DNA TOPOISOMERASE; DOXORUBICIN; EVEROLIMUS; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HYPOXIA INDUCIBLE FACTOR; IDARUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLCHOLINE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; RAPAMYCIN; SALICYLIC ACID; SALSALATE; SILIBININ; SILIPHOS; SUNITINIB; TOPOTECAN; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER INVASION; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SENSITIVITY; GLIOBLASTOMA; HEARING LOSS; HUMAN; HYPOXIA; LEWIS CARCINOMA; LOW DRUG DOSE; NONHUMAN; PROSTATE CANCER; PROTEIN DNA BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SPIRULINA; STOMACH CANCER; TINNITUS; TRANSLATION REGULATION;

ANGIOGENESIS INHIBITORS; ANTHRACYCLINES; CARDIAC GLYCOSIDES; CELL HYPOXIA; DNA TOPOISOMERASES, TYPE I; GENE EXPRESSION REGULATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM INVASIVENESS; NEOPLASMS; NF-KAPPA B; PROTEIN-SERINE-THREONINE KINASES; SALICYLIC ACID; SILYMARIN;

RODENTIA;

EID: 77950922592     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.12.022     Document Type: Article

References (179)

1. Vaupel P., Kelleher D.K., Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 2001, 28(2 Suppl. 8):29-35.
2. Brahimi-Horn M.C., Chiche J., Pouyssegur J. Hypoxia and cancer. J Mol Med 2007, 85(12):1301-1307.
3. Vaupel P., Mayer A. Hypoxia and anemia: effects on tumor biology and treatment resistance. Transfus Clin Biol 2005, 12(1):5-10.
4. Hill R.P., De J.K., Jang A., Cairns R. pH, hypoxia and metastasis. Novartis Found Symp 2001, 240:154-165.
5. Harris A.L. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2(1):38-47.
6. Vaupel P., Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007, 26(2):225-239.
7. Ruan K., Song G., Ouyang G. Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 2009, 107(6):1053-1062.
8. Rubenstein J.L., Kim J., Ozawa T., Zhang M., Westphal M., Deen D.F., et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000, 2(4):306-314.
9. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15(3):220-231.
10. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15(3):232-239.
11. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8(4):299-309.
12. Ebos J.M., Lee C.R., Kerbel R.S. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 2009, 15(16):5020-5025.
13. Blagosklonny M.V. Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review). Int J Oncol 2001, 19(2):257-262.
14. Powis G., Kirkpatrick L. Hypoxia inducible factor-1alpha as a cancer drug target. Mol Cancer Ther 2004, 3(5):647-654.
15. Gort E.H., Groot A.J., van der W.E., van Diest P.J., Vooijs M.A. Hypoxic regulation of metastasis via hypoxia-inducible factors. Curr Mol Med 2008, 8(1):60-67.
16. Semenza G.L. Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE 2007, 2007(407):cm8.
17. Liu Y.V., Semenza G.L. RACK1 vs. HSP90: competition for HIF-1 alpha degradation vs. stabilization. Cell Cycle 2007, 6(6):656-659.
18. Semenza G.L. HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J Bioenerg Biomembr 2007, 39(3):231-234.
19. Minchenko A., Leshchinsky I., Opentanova I., Sang N., Srinivas V., Armstead V., et al. Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effect. J Biol Chem 2002, 277(8):6183-6187.
20. Robey I.F., Lien A.D., Welsh S.J., Baggett B.K., Gillies R.J. Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors. Neoplasia 2005, 7(4):324-330.
21. Liao D., Johnson R.S. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 2007, 26(2):281-290.
22. Nakamura M., Yamabe H., Osawa H., Nakamura N., Shimada M., Kumasaka R., et al. Hypoxic conditions stimulate the production of angiogenin and vascular endothelial growth factor by human renal proximal tubular epithelial cells in culture. Nephrol Dial Transplant 2006, 21(6):1489-1495.
23. Brown L.M., Cowen R.L., Debray C., Eustace A., Erler J.T., Sheppard F.C., et al. Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Mol Pharmacol 2006, 69(2):411-418.
24. Liu L., Ning X., Sun L., Zhang H., Shi Y., Guo C., et al. Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci 2008, 99(1):121-128.
25. Nardinocchi L., Puca R., Sacchi A., D'Orazi G. Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis. Mol Cancer 2009, 8:1.
26. Lau C.K., Yang Z.F., Ho D.W., Ng M.N., Yeoh G.C., Poon R.T., et al. An Akt/hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells. Clin Cancer Res 2009, 15(10):3462-3471.
27. Comerford K.M., Wallace T.J., Karhausen J., Louis N.A., Montalto M.C., Colgan S.P. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002, 62(12):3387-3394.
28. Cannito S., Novo E., Compagnone A., Valfre di B.L., Busletta C., Zamara E., et al. Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis 2008, 29(12):2267-2278.
29. Jiang Y.G., Luo Y., He D.L., Li X., Zhang L.L., Peng T., et al. Role of Wnt/beta-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor-1alpha. Int J Urol 2007, 14(11):1034-1039.
30. Shin D.H., Kim J.H., Jung Y.J., Kim K.E., Jeong J.M., Chun Y.S., et al. Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading. Cancer Lett 2007, 255(1):107-116.
31. Elstner A., Holtkamp N., von D.A. Involvement of Hif-1 in desferrioxamine-induced invasion of glioblastoma cells. Clin Exp Metastasis 2007, 24(1):57-66.
32. Shyu K.G., Hsu F.L., Wang M.J., Wang B.W., Lin S. Hypoxia-inducible factor 1alpha regulates lung adenocarcinoma cell invasion. Exp Cell Res 2007, 313(6):1181-1191.
33. Fujiwara S., Nakagawa K., Harada H., Nagato S., Furukawa K., Teraoka M., et al. Silencing hypoxia-inducible factor-1alpha inhibits cell migration and invasion under hypoxic environment in malignant gliomas. Int J Oncol 2007, 30(4):793-802.
34. Luo Y., He D.L., Ning L., Shen S.L., Li L., Li X., et al. Over-expression of hypoxia-inducible factor-1alpha increases the invasive potency of LNCaP cells in vitro. BJU Int 2006, 98(6):1315-1319.
35. Ide T., Kitajima Y., Miyoshi A., Ohtsuka T., Mitsuno M., Ohtaka K., et al. Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway. Int J Cancer 2006, 119(12):2750-2759.
36. Hara S., Nakashiro K., Klosek S.K., Ishikawa T., Shintani S., Hamakawa H. Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1alpha in human salivary gland cancer cells. Oral Oncol 2006, 42(6):593-598.
37. Chen H.H., Su W.C., Lin P.W., Guo H.R., Lee W.Y. Hypoxia-inducible factor-1alpha correlates with MET and metastasis in node-negative breast cancer. Breast Cancer Res Treat 2007, 103(2):167-175.
38. Eckerich C., Zapf S., Fillbrandt R., Loges S., Westphal M., Lamszus K. Hypoxia can induce c-Met expression in glioma cells and enhance SF/HGF-induced cell migration. Int J Cancer 2007, 121(2):276-283.
39. Kitajima Y., Ide T., Ohtsuka T., Miyazaki K. Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer. Cancer Sci 2008, 99(7):1341-1347.
40. Pennacchietti S., Michieli P., Galluzzo M., Mazzone M., Giordano S., Comoglio P.M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003, 3(4):347-361.
41. Corso S., Migliore C., Ghiso E., De R.G., Comoglio P.M., Giordano S. Silencing the MET oncogene leads to regression of experimental tumors and metastases. Oncogene 2008, 27(5):684-693.
42. Knudsen B.S., Vande W.G. Showering c-MET-dependent cancers with drugs. Curr Opin Genet Dev 2008, 18(1):87-96.
43. Patiar S., Harris A.L. Role of hypoxia-inducible factor-1alpha as a cancer therapy target. Endocr Relat Cancer 2006, 13(Suppl. 1):S61-S75.
44. Bonello S., Zahringer C., BelAiba R.S., Djordjevic T., Hess J., Michiels C., et al. Reactive oxygen species activate the HIF-1alpha promoter via a functional NFkappaB site. Arterioscler Thromb Vasc Biol 2007, 27(4):755-761.
45. BelAiba R.S., Bonello S., Zahringer C., Schmidt S., Hess J., Kietzmann T., et al. Hypoxia up-regulates hypoxia-inducible factor-1alpha transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells. Mol Biol Cell 2007, 18(12):4691-4697.
46. Rius J., Guma M., Schachtrup C., Akassoglou K., Zinkernagel A.S., Nizet V., et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 2008, 453(7196):807-811.
47. Aggarwal B.B. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004, 6(3):203-208.
48. Wu J.T., Kral J.G. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Surg Res 2005, 123(1):158-169.
49. Takada Y., Andreeff M., Aggarwal B.B. Indole-3-carbinol suppresses NF-kappaB and IkappaBalpha kinase activation, causing inhibition of expression of NF-kappaB-regulated antiapoptotic and metastatic gene products and enhancement of apoptosis in myeloid and leukemia cells. Blood 2005, 106(2):641-649.
50. Takada Y., Murakami A., Aggarwal B.B. Zerumbone abolishes NF-kappaB and IkappaBalpha kinase activation leading to suppression of antiapoptotic and metastatic gene expression, upregulation of apoptosis, and downregulation of invasion. Oncogene 2005.
51. Bancroft C.C., Chen Z., Dong G., Sunwoo J.B., Yeh N., Park C., et al. Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways. Clin Cancer Res 2001, 7(2):435-442.
52. Wang C.Y., Cusack J.C., Liu R., Baldwin A.S. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999, 5(4):412-417.
53. Cusack J.C., Liu R., Baldwin A.S. NF-kappaB and chemoresistance: potentiation of cancer drugs via inhibition of NF-kappaB. Drug Resist Updat 1999, 2(4):271-273.
54. Bentires-Alj M., Barbu V., Fillet M., Chariot A., Relic B., Jacobs N., et al. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 2003, 22(1):90-97.
55. Nakanishi C., Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005, 5(4):297-309.
56. Koong A.C., Chen E.Y., Giaccia A.J. Hypoxia causes the activation of nuclear factor kappaB through the phosphorylation of I kappaB alpha on tyrosine residues. Cancer Res 1994, 54(6):1425-1430.
57. Xu L., Xie K., Mukaida N., Matsushima K., Fidler I.J. Hypoxia-induced elevation in interleukin-8 expression by human ovarian carcinoma cells. Cancer Res 1999, 59(22):5822-5829.
58. Karashima T., Sweeney P., Kamat A., Huang S., Kim S.J., Bar-Eli M., et al. Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. Clin Cancer Res 2003, 9(7):2786-2797.
59. Qanungo S., Wang M., Nieminen A.L. N-Acetyl-l-cysteine enhances apoptosis through inhibition of nuclear factor-kappaB in hypoxic murine embryonic fibroblasts. J Biol Chem 2004, 279(48):50455-50464.
60. Kimba Y., Abe T., Wu J.L., Inoue R., Fukiki M., Kohno K., et al. Mutant IkappaBalpha suppresses hypoxia-induced VEGF expression through downregulation of HIF-1alpha and COX-2 in human glioma cells. Oncol Res 2005, 15(3):139-149.
61. Oliver K.M., Garvey J.F., Ng C.T., Veale D.J., Fearon U., Cummins E.P., et al. Hypoxia activates NF-kappaB-dependent gene expression through the canonical signaling pathway. Antioxid Redox Signal 2009.
62. Cummins E.P., Berra E., Comerford K.M., Ginouves A., Fitzgerald K.T., Seeballuck F., et al. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci USA 2006, 103(48):18154-18159.
63. Cummins E.P., Comerford K.M., Scholz C., Bruning U., Taylor C.T. Hypoxic regulation of NF-kappaB signaling. Methods Enzymol 2007, 435:479-492.
64. Kopp E., Ghosh S. Inhibition of NF-kappaB by sodium salicylate and aspirin. Science 1994, 265(5174):956-959.
65. Yin M.J., Yamamoto Y., Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998, 396(6706):77-80.
66. Pierce G.L., Lesniewski L.A., Lawson B.R., Beske S.D., Seals D.R. Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans. Circulation 2009, 119(9):1284-1292.
67. Goldfine A.B., Silver R., Aldhahi W., Cai D., Tatro E., Lee J., et al. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci 2008, 1(1):36-43.
68. Atkinson M.H., Menard H.A., Kalish G.H. Assessment of salsalate, a nonacetylated salicylate, in the treatment of patients with arthritis. Clin Ther 1995, 17(5):827-837.
69. Singleton P.T. Salsalate: its role in the management of rheumatic disease. Clin Ther 1980, 3(2):80-102.
70. Brien J.A. Ototoxicity associated with salicylates. A brief review. Drug Saf 1993, 9(2):143-148.
71. Bombardier C., Peloso P.M., Goldsmith C.H. Salsalate, a nonacetylated salicylate, is as efficacious as diclofenac in patients with rheumatoid arthritis. Salsalate-diclofenac study group. J Rheumatol 1995, 22(4):617-624.
72. Morris H.G., Sherman N.A., McQuain C., Goldlust M.B., Chang S.F., Harrison L.I. Effects of salsalate (nonacetylated salicylate) and aspirin on serum prostaglandins in humans. Ther Drug Monit 1985, 7(4):435-438.
73. Roth S., Bennett R., Caldron P., Hartman R., Mitchell C., Doucette M., et al. Reduced risk of NSAID gastropathy (GI mucosal toxicity) with nonacetylated salicylate (salsalate): an endoscopic study. Semin Arthritis Rheum 1990, 19(4 Suppl. 2):11-19.
74. Robert A. Gastric cytoprotection by sodium salicylate. Prostaglandins 1981, 21(Suppl.):139-146.
75. McCarty M.F., Block K.I. Preadministration of high-dose salicylates, suppressors of NF-kappaB activation, may increase the chemosensitivity of many cancers: an example of proapoptotic signal modulation therapy. Integr Cancer Ther 2006, 5(3):252-268.
76. Dhanalakshmi S., Singh R.P., Agarwal C., Agarwal R. Silibinin inhibits constitutive and TNFalpha-induced activation of NF-kappaB and sensitizes human prostate carcinoma DU145 cells to TNFalpha-induced apoptosis. Oncogene 2002, 21(11):1759-1767.
77. Singh R.P., Mallikarjuna G.U., Sharma G., Dhanalakshmi S., Tyagi A.K., Chan D.C., et al. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance. Clin Cancer Res 2004, 10(24):8641-8647.
78. Tyagi A., Singh R.P., Ramasamy K., Raina K., Redente E.F., Dwyer-Nield L.D., et al. Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kappaB and signal transducers and activators of transcription 3. Cancer Prev Res (Phila Pa) 2009, 2(1):74-83.
79. Cui W., Gu F., Hu K.Q. Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice. World J Gastroenterol 2009, 15(16):1943-1950.
80. Singh R.P., Sharma G., Dhanalakshmi S., Agarwal C., Agarwal R. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Cancer Epidemiol Biomarkers Prev 2003, 12(9):933-939.
81. Singh R.P., Tyagi A., Sharma G., Mohan S., Agarwal R. Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down-regulation of survivin. Clin Cancer Res 2008, 14(1):300-308.
82. Singh R.P., Gu M., Agarwal R. Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Res 2008, 68(6):2043-2050.
83. Kaur M., Velmurugan B., Tyagi A., Deep G., Katiyar S., Agarwal C., et al. Silibinin suppresses growth and induces apoptotic death of human colorectal carcinoma LoVo cells in culture and tumor xenograft. Mol Cancer Ther 2009, 8(8):2366-2374.
84. Flaig T.W., Gustafson D.L., Su L.J., Zirrolli J.A., Crighton F., Harrison G.S., et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs 2007, 25(2):139-146.
85. Yoshimura S., Bondeson J., Foxwell B.M., Brennan F.M., Feldmann M. Effective antigen presentation by dendritic cells is NF-kappaB dependent: coordinate regulation of MHC, co-stimulatory molecules and cytokines. Int Immunol 2001, 13(5):675-683.
86. Lee J.S., Kim S.G., Kim H.K., Lee T.H., Jeong Y.I., Lee C.M., et al. Silibinin polarizes Th1/Th2 immune responses through the inhibition of immunostimulatory function of dendritic cells. J Cell Physiol 2007, 210(2):385-397.
87. Matasic R., Dietz A.B., Vuk-Pavlovic S. Cyclooxygenase-independent inhibition of dendritic cell maturation by aspirin. Immunology 2000, 101(1):53-60.
88. Min K., Yoon W.K., Kim S.K., Kim B.H. Immunosuppressive effect of silibinin in experimental autoimmune encephalomyelitis. Arch Pharm Res 2007, 30(10):1265-1272.
89. Laughner E., Taghavi P., Chiles K., Mahon P.C., Semenza G.L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001, 21(12):3995-4004.
90. Thomas G.V., Tran C., Mellinghoff I.K., Welsbie D.S., Chan E., Fueger B., et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006, 12(1):122-127.
91. Garcia-Maceira P., Mateo J. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy. Oncogene 2009, 28(3):313-324.
92. Ngo T.H., Barnard R.J., Tymchuk C.N., Cohen P., Aronson W.J. Effect of diet and exercise on serum insulin, IGF-I, and IGFBP-1 levels and growth of LNCaP cells in vitro (United States). Cancer Causes Control 2002, 13(10):929-935.
93. Ornish D., Weidner G., Fair W.R., Marlin R., Pettengill E.B., Raisin C.J., et al. Intensive lifestyle changes may affect the progression of prostate cancer. J Urol 2005, 174(3):1065-1069.
94. McCarty M.F. Insulin and IGF-I as determinants of low " Western" cancer rates in the rural third world. Int J Epidemiol 2004, 33(4):908-910.
95. Rapisarda A., Uranchimeg B., Sordet O., Pommier Y., Shoemaker R.H., Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 2004, 64(4):1475-1482.
96. Rapisarda A., Zalek J., Hollingshead M., Braunschweig T., Uranchimeg B., Bonomi C.A., et al. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 2004, 64(19):6845-6848.
97. Puppo M., Battaglia F., Ottaviano C., Delfino S., Ribatti D., Varesio L., et al. Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha. Mol Cancer Ther 2008, 7(7):1974-1984.
98. Beppu K., Nakamura K., Linehan W.M., Rapisarda A., Thiele C.J. Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells. Cancer Res 2005, 65(11):4775-4781.
99. Rapisarda A., Hollingshead M., Uranchimeg B., Bonomi C.A., Borgel S.D., Carter J.P., et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther 2009, 8(7):1867-1877.
100. Cejka D., Preusser M., Woehrer A., Sieghart W., Strommer S., Werzowa J., et al. Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. Cancer Biol Ther 2008, 7(9):1377-1385.
101. Pencreach E., Guerin E., Nicolet C., Lelong-Rebel I., Voegeli A.C., Oudet P., et al. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis. Clin Cancer Res 2009, 15(4):1297-1307.
102. Soepenberg O., Dumez H., Verweij J., de Jong F.A., de Jonge M.J., Thomas J., et al. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors. Clin Cancer Res 2005, 11(4):1504-1511.
103. Kuppens I.E., Dansin E., Boot H., Feger C., Assadourian S., Bonneterre M.E., et al. Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors. Clin Cancer Res 2006, 12(12):3774-3781.
104. Allegrini G., Falcone A., Fioravanti A., Barletta M.T., Orlandi P., Loupakis F., et al. A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. Br J Cancer 2008, 98(8):1312-1319.
105. Zhang H., Qian D.Z., Tan Y.S., Lee K., Gao P., Ren Y.R., et al. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci USA 2008, 105(50):19579-19586.
106. Lopez-Lazaro M. Digoxin, HIF-1, and cancer. Proc Natl Acad Sci USA 2009, 106(9):E26.
107. Newman R.A., Yang P., Pawlus A.D., Block K.I. Cardiac glycosides as novel cancer therapeutic agents. Mol Interv 2008, 8(1):36-49.
108. Al-Ghoul M., Valdes R. Mammalian cardenolides in cancer prevention and therapeutics. Ther Drug Monit 2008, 30(2):234-238.
109. Khan M.I., Chesney J.A., Laber D.A., Miller D.M. Digitalis, a targeted therapy for cancer?. Am J Med Sci 2009, 337(5):355-359.
110. Lopez-Lazaro M., Pastor N., Azrak S.S., Ayuso M.J., Austin C.A., Cortes F. Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients. J Nat Prod 2005, 68(11):1642-1645.
111. Gerald D., Berra E., Frapart Y.M., Chan D.A., Giaccia A.J., Mansuy D., et al. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 2004, 118(6):781-794.
112. BelAiba R.S., Djordjevic T., Bonello S., Flugel D., Hess J., Kietzmann T., et al. Redox-sensitive regulation of the HIF pathway under non-hypoxic conditions in pulmonary artery smooth muscle cells. Biol Chem 2004, 385(3-4):249-257.
113. Pan Y., Mansfield K.D., Bertozzi C.C., Rudenko V., Chan D.A., Giaccia A.J., et al. Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro. Mol Cell Biol 2007, 27(3):912-925.
114. Page E.L., Chan D.A., Giaccia A.J., Levine M., Richard D.E. Hypoxia-inducible factor-1alpha stabilization in nonhypoxic conditions: role of oxidation and intracellular ascorbate depletion. Mol Biol Cell 2008, 19(1):86-94.
115. Lu H., Dalgard C.L., Mohyeldin A., McFate T., Tait A.S., Verma A. Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J Biol Chem 2005, 280(51):41928-41939.
116. 2 sensing. J Biol Chem 2000, 275(33):25130-25138.
117. Schroedl C., McClintock D.S., Budinger G.R., Chandel N.S. Hypoxic but not anoxic stabilization of HIF-1alpha requires mitochondrial reactive oxygen species. Am J Physiol Lung Cell Mol Physiol 2002, 283(5):L922-L931.
118. Guzy R.D., Schumacker P.T. Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. Exp Physiol 2006, 91(5):807-819.
119. Arnold R.S., Shi J., Murad E., Whalen A.M., Sun C.Q., Polavarapu R., et al. Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1. Proc Natl Acad Sci USA 2001, 98(10):5550-5555.
120. Brar S.S., Kennedy T.P., Sturrock A.B., Huecksteadt T.P., Quinn M.T., Whorton A.R., et al. An NAD(P)H oxidase regulates growth and transcription in melanoma cells. Am J Physiol Cell Physiol 2002, 282(6):C1212-C1224.
121. Brar S.S., Corbin Z., Kennedy T.P., Hemendinger R., Thornton L., Bommarius B., et al. NOX5 NAD(P)H oxidase regulates growth and apoptosis in DU 145 prostate cancer cells. Am J Physiol Cell Physiol 2003, 285(2):C353-C369.
122. Brar S.S., Kennedy T.P., Quinn M., Hoidal J.R. Redox signaling of NF-kappaB by membrane NAD(P)H oxidases in normal and malignant cells. Protoplasma 2003, 221(1-2):117-127.
123. McCarty M.F., Barroso-Aranda J., Contreras F. A two-phase strategy for treatment of oxidant-dependent cancers. Med Hypotheses 2007, 69(3):489-496.
124. Goyal P., Weissmann N., Grimminger F., Hegel C., Bader L., Rose F., et al. Upregulation of NAD(P)H oxidase 1 in hypoxia activates hypoxia-inducible factor 1 via increase in reactive oxygen species. Free Radic Biol Med 2004, 36(10):1279-1288.
125. Biswas S., Gupta M.K., Chattopadhyay D., Mukhopadhyay C.K. Insulin-induced activation of hypoxia-inducible factor-1 requires generation of reactive oxygen species by NADPH oxidase. Am J Physiol Heart Circ Physiol 2007, 292(2):H758-H766.
126. Xia C., Meng Q., Liu L.Z., Rojanasakul Y., Wang X.R., Jiang B.H. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res 2007, 67(22):10823-10830.
127. McCarty M.F. Clinical potential of Spirulina as a source of phycocyanobilin. J Med Food 2007, 10(4):566-570.
128. Atkuri K.R., Mantovani J.J., Herzenberg L.A., Herzenberg L.A. N-Acetylcysteine - a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol 2007, 7(4):355-359.
129. Gao P., Zhang H., Dinavahi R., Li F., Xiang Y., Raman V., et al. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 2007, 12(3):230-238.
130. Moertel C.G., Fleming T.R., Creagan E.T., Rubin J., O'Connell M.J., Ames M.M. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 1985, 312(3):137-141.
131. Aitio M.L. N-Acetylcysteine - passe-partout or much ado about nothing?. Br J Clin Pharmacol 2006, 61(1):5-15.
132. Levine M., Conry-Cantilena C., Wang Y., Welch R.W., Washko P.W., Dhariwal K.R., et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci USA 1996, 93(8):3704-3709.
133. McFate T., Mohyeldin A., Lu H., Thakar J., Henriques J., Halim N.D., et al. Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem 2008, 283(33):22700-22708.
134. Stacpoole P.W., Henderson G.N., Yan Z., James M.O. Clinical pharmacology and toxicology of dichloroacetate. Environ Health Perspect 1998, 106(Suppl. 4):989-994.
135. Michelakis E.D., Webster L., Mackey J.R. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 2008, 99(7):989-994.
136. Sun R.C., Fadia M., Dahlstrom J.E., Parish C.R., Board P.G., Blackburn A.C. Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo. Breast Cancer Res Treat 2009.
137. + channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007, 11(1):37-51.
138. Matsumoto K., Imagawa S., Obara N., Suzuki N., Takahashi S., Nagasawa T., et al. 2-Oxoglutarate downregulates expression of vascular endothelial growth factor and erythropoietin through decreasing hypoxia-inducible factor-1alpha and inhibits angiogenesis. J Cell Physiol 2006, 209(2):333-340.
139. Matsumoto K., Obara N., Ema M., Horie M., Naka A., Takahashi S., et al. Antitumor effects of 2-oxoglutarate through inhibition of angiogenesis in a murine tumor model. Cancer Sci 2009, 100(9):1639-1647.
140. Mabjeesh N.J., Post D.E., Willard M.T., Kaur B., Van Meir E.G., Simons J.W., et al. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 2002, 62(9):2478-2482.
141. Isaacs J.S., Jung Y.J., Mimnaugh E.G., Martinez A., Cuttitta F., Neckers L.M. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 2002, 277(33):29936-29944.
142. Zagzag D., Nomura M., Friedlander D.R., Blanco C.Y., Gagner J.P., Nomura N., et al. Geldanamycin inhibits migration of glioma cells in vitro: a potential role for hypoxia-inducible factor (HIF-1alpha) in glioma cell invasion. J Cell Physiol 2003, 196(2):394-402.
143. Alqawi O., Moghaddas M., Singh G. Effects of geldanamycin on HIF-1alpha mediated angiogenesis and invasion in prostate cancer cells. Prostate Cancer Prostatic Dis 2006, 9(2):126-135.
144. Koga F., Tsutsumi S., Neckers L.M. Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells. Cell Cycle 2007, 6(11):1393-1402.
145. Minet E., Arnould T., Michel G., Roland I., Mottet D., Raes M., et al. ERK activation upon hypoxia: involvement in HIF-1 activation. FEBS Lett 2000, 468(1):53-58.
146. Mylonis I., Chachami G., Samiotaki M., Panayotou G., Paraskeva E., Kalousi A., et al. Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha. J Biol Chem 2006, 281(44):33095-33106.
147. Mylonis I., Chachami G., Paraskeva E., Simos G. Atypical CRM1-dependent nuclear export signal mediates regulation of hypoxia-inducible factor-1alpha by MAPK. J Biol Chem 2008, 283(41):27620-27627.
148. Lee K., Qian D.Z., Rey S., Wei H., Liu J.O., Semenza G.L. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci USA 2009, 106(7):2353-2358.
149. Stewart D.J., Grewaal D., Green R.M., Verma S., Maroun J.A., Redmond D., et al. Bioavailability and pharmacology of oral idarubicin. Cancer Chemother Pharmacol 1991, 27(4):308-314.
150. Camaggi C.M., Strocchi E., Carisi P., Martoni A., Tononi A., Guaraldi M., et al. Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. Cancer Chemother Pharmacol 1992, 30(4):307-316.
151. Schleyer E., Kuhn S., Ruhrs H., Unterhalt M., Kaufmann C.C., Kern W., et al. Oral idarubicin pharmacokinetics - correlation of trough level with idarubicin area under curve. Leukemia 1997, 11(Suppl. 5):S15-S21.
152. Toffoli G., Sorio R., Aita P., Crivellari D., Corona G., Bearz A., et al. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients. Clin Cancer Res 2000, 6(6):2279-2287.
153. Crivellari D., Lombardi D., Corona G., Massacesi C., Talamini R., Sorio R., et al. Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring. Ann Oncol 2006, 17(5):807-812.
154. Conklin K.A. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. Integr Cancer Ther 2005, 4(2):110-130.
155. Khan M., Varadharaj S., Shobha J.C., Naidu M.U., Parinandi N.L., Kutala V.K., et al. C-Phycocyanin ameliorates doxorubicin-induced oxidative stress and apoptosis in adult rat cardiomyocytes. J Cardiovasc Pharmacol 2006, 47(1):9-20.
156. Khan M., Shobha J.C., Mohan I.K., Naidu M.U., Sundaram C., Singh S., et al. Protective effect of Spirulina against doxorubicin-induced cardiotoxicity. Phytother Res 2005, 19(12):1030-1037.
157. Gilleron M., Marechal X., Montaigne D., Franczak J., Neviere R., Lancel S. NADPH oxidases participate to doxorubicin-induced cardiac myocyte apoptosis. Biochem Biophys Res Commun 2009.
158. Crivellari D., Lombardi D., Spazzapan S., Veronesi A., Toffoli G. New oral drugs in older patients: a review of idarubicin in elderly patients. Crit Rev Oncol Hematol 2004, 49(2):153-163.
159. Spitz D.R., Sim J.E., Ridnour L.A., Galoforo S.S., Lee Y.J. Glucose deprivation-induced oxidative stress in human tumor cells. A fundamental defect in metabolism?. Ann N Y Acad Sci 2000, 899:349-362.
160. 2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. Biochem J 2009, 418(1):29-37.
161. Wang H.Y., Hochwald S., Port J., Harrison L.E., Ng B., Burt M. Hypoglycemia with glycerol salvage: a role in anti-neoplastic therapy?. Anticancer Res 1995, 15(4):1343-1348.
162. McCarty M.F. Prospects for glycerol-rescued hypoglycemia as a cancer therapy. Med Hypotheses 2001, 56(3):286-289.
163. Nijsten M.W., van Dam G.M. Hypothesis: using the Warburg effect against cancer by reducing glucose and providing lactate. Med Hypotheses 2009, 73(1):48-51.
164. Akakura N., Kobayashi M., Horiuchi I., Suzuki A., Wang J., Chen J., et al. Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 2001, 61(17):6548-6554.
165. Williams K.J., Telfer B.A., Airley R.E., Peters H.P., Sheridan M.R., van der Kogel A.J., et al. A protective role for HIF-1 in response to redox manipulation and glucose deprivation: implications for tumorigenesis. Oncogene 2002, 21(2):282-290.
166. Guo S., Miyake M., Liu K.J., Shi H. Specific inhibition of hypoxia inducible factor 1 exaggerates cell injury induced by in vitro ischemia through deteriorating cellular redox environment. J Neurochem 2009, 108(5):1309-1321.
167. Kabashima K., Honda T., Nunokawa Y., Miyachi Y. A new NF-kappaB inhibitor attenuates a TH1 type immune response in a murine model. FEBS Lett 2004, 578(1-2):36-40.
168. Andreakos E., Williams R.O., Wales J., Foxwell B.M., Feldmann M. Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant. Proc Natl Acad Sci USA 2006, 103(39):14459-14464.
169. Kim G.Y., Kim K.H., Lee S.H., Yoon M.S., Lee H.J., Moon D.O., et al. Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF-kappaB as potential targets. J Immunol 2005, 174(12):8116-8124.
170. Buckland M., Lombardi G. Aspirin and the induction of tolerance by dendritic cells. Handb Exp Pharmacol 2009, (188):197-213.
171. Hahnel P.S., Thaler S., Antunes E., Huber C., Theobald M., Schuler M. Targeting AKT signaling sensitizes cancer to cellular immunotherapy. Cancer Res 2008, 68(10):3899-3906.
172. Weichhart T., Costantino G., Poglitsch M., Rosner M., Zeyda M., Stuhlmeier K.M., et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008, 29(4):565-577.
173. Zheng Y., Collins S.L., Lutz M.A., Allen A.N., Kole T.P., Zarek P.E., et al. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J Immunol 2007, 178(4):2163-2170.
174. Thomson A.W., Turnquist H.R., Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009, 9(5):324-337.
175. Finke J.H., Rini B., Ireland J., Rayman P., Richmond A., Golshayan A., et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008, 14(20):6674-6682.
176. Ko J.S., Zea A.H., Rini B.I., Ireland J.L., Elson P., Cohen P., et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009, 15(6):2148-2157.
177. Ozao-Choy J., Ma G., Kao J., Wang G.X., Meseck M., Sung M., et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009, 69(6):2514-2522.
178. Corzo C.A., Cotter M.J., Cheng P., Cheng F., Kusmartsev S., Sotomayor E., et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 2009, 182(9):5693-5701.
179. Mehrotra S., Mougiakakos D., Johansson C.C., Voelkel-Johnson C., Kiessling R. Oxidative stress and lymphocyte persistence: implications in immunotherapy. Adv Cancer Res 2009, 102:197-227.